TSUMURA & CO.

TSUMURA & CO. Second Quarter Business Results for Fiscal 2019

(From April 1, 2019 to September 30, 2019)

November 7, 2019

Muneki Handa Director and Excecutive Officer, CFO

2Q Consolidated Performance for Fiscal 2019

(¥ million)


TSUMURA & CO.

2Q, FY2019

	FY 2019	FY 2019	Achievement	FY 2018	Vs. FY 2018 2Q	
	2Q Plan	2Q	Admevement	2Q	Amount	Change
Net sales	61,500	60,802	98.9%	58,268	2,533	4.3%
Operating profit	8,100	9,776	120.7%	8,950	826	9.2%
Operating profit margin	13.2%	16.1%	-	15.4%	-	-
Ordinary profit	8,700	9,856	113.3%	9,566	290	3.0%
Profit attributable to owners of parent	6,000	7,037	117.3%	7,082	(44)	(0.6)%

	FY 2019	FY 2019	FY 2018
	2Q Plan	2Q	2Q
Dividends per share	¥32	¥32	¥32

Sales by product



Key Points in Performance

Net sales were up year-on-year but profits were down marginally. Net sales undershot plans but profits at all levels achieved plans.

Сс	onsolidated net sales	¥60,802 million	Vs. planned	98.9%	YoY	4.3%
	Net sales of the 129 presc On a yen-basis, sales rose Net sales of OTC medicine	for 87 prescriptions.		ear.		
0	perating profit	¥9,776 million	Vs. planned	120.7%	YoY	9.2%
O	perating profit margin	16.1 %			YoY	+0.7pt
	The cost-to-sales ratio sto down, this rise reflected in due to a delay in the timin The cost-to-SG&A ratio w increase in sales rebates mainly to a delay in the tim	ig of impact from unrealize as 43.0%, down 1.2pt from and R&D costs. The cost-	fit. The cost-to-sale ed profit. n a year earlier, ow to-SG&A ratio was	es ratio also un ving to a rise in also 2.0pt lowe	dershot pla sales and o	ns by 0.9pt, despite the
0	dinary profit	¥9,856 million	Vs. planned	113.3%	YoY	3.0%



Owing to this, 2Q net income was down 0.6% year-on-year but up 17.3% versus plans.

TSUMURA & CO.

Factors for changes in Operating Profit

				(¥ million)		(¥ million)
	+1,510	(335)			Profit impact from ch sales cost	anges in
			(349)		Decrease of crude drug cost	+486
				9,776	Increase of unrealized profit	(670)
					Other	(151)
8,950					Profit impact from ch SG&A expenses	nanges in
					Sales promotion expenses	(238)
					R&D expenses	(142)
					Personnel expenses	(113)
FY 2018 2Q Operating profit	Profit impact from changes [†] in sales	Profit impact from changes in sales cost margin	Profit impact from changes in SG&A expenses	FY 2019 2Q Operating profit	Other	+144

TSUMURA & CO.

2Q, FY2019

Financial Condition / Cash Flow Position

Balance Sheet			(¥ million)							
	As of March 2019	As of September 2019	Change	Ca	ash	Flow	Positio	on	Effect of	¥ billion)
Total assets	287,322	287,010	(312)		_		•	Financing	Tale	
Current assets	190,027	187,678	(2,349)			Activities	+4.7	Activities (2.5)	Changes	
Non-current assets	97,295	99,331	2,036			+8.6		()	(0.3)	66.8
Total liabilities	81,181	80,170	(1,010)	56	2					
Current liabilities	33,320	33,222	(97)		• 4					
Non-current liabilities	47,861	46,948	(912)							
Total net assets	206,141	206,839	697							
Equity Ratio	70.2%	70.6%	0.4pt							
			(¥ million))						
Balance Sheet	As of March 2019	As of September 2019	Change							
Inventories	51,808	56,726	4,917							
(Merchandise and finishedgoods)	9,382	7,258	(2,124)	Cash a equiv	aler	nts			equ	and cash ivalents
(Work in process)	11,125	13,493	2,367	at begi	nnir riod	•			at end	d of period
(Raw materials and stores)	31,299	35,974	4,675		iiuu					5

TSUMURA & CO. 2Q, FY2019

Roadmap to Realizing Our Long-Term Vision



Strategic Challenges

- 1. Sustainably expanding the Kampo market and establishing presence
- 2. Investing in growth and building business foundations in China
- 3. Improving productivity using new technology (AI, Automation, RPA)
- 4. Fostering a corporate culture through philosophy-based management and developing diverse human resources
- 5. Promoting SDGs through the Kampo Value Chain

TSUMURA & CO.

Sales performance of prescription Kampo products

(¥ million)

	Sales rank	Pro	duct No. / name	FY 2018 2Q	FY 2019 2Q	YoY C	hange	
	1	100	Daikenchuto	5,226	5,262	36	0.7%	
erinç ns *	2	54	Yokukansan	3,848	3,953	104	2.7%	
fost	3	43	Rikkunshito	3,559	3,719	160	4.5%	
Drug-fostering formulations *1	9	107	Goshajinkigan	1,806	1,831	25	1.4%	
с ç	22	14	Hangeshashinto	670	717	47	7.0%	V
То	Total sales of the five Drug-fostering formulations		15,110	15,484	373	2.5%		
	4	41	Hochuekkito	3,680	3,670	(9)	(0.3)%	
ing ons *2	5	68	Shakuyakukanzo to	2,629	2,724	94	3.6%	
Growing	8	29	Bakumondoto	2,004	2,210	206	10.3%	
form	6	24	Kamishoyosan	2,263	2,348	84	3.7%	
	7	17	Goreisan	2,112	2,318	206	9.8%	
		es of the formula	e five Growing tions	12,691	13,273	581	4.6%	
	Total of 12	9 preso produ	ription Kampo cts	55,799	58,141	2,341	4.2%	

Major factors triggering underperformance in 1H

20, FY2019

Sales of "Drug
Fostering" program
formulations, which
account for 25% of
total sales, grew
2.5% YoY
(Total sales growth
for overall
prescription Kampo
products was 4.2%)

*1 Looking at the recent structure of disease, the Company has selected certain diseases in fields where medical treatment needs are high that are difficult to treat with Western drugs and that Kampo products have demonstrated special efficacy for. The Company will establish a base of scientific evidence related to treating these diseases with Kampo medicine.

*2 A growth driver that aims to be listed in medical treatment guidelines as a strategic formulation following the five "drug fostering" program formulations through the establishment of scientific evidence (data on safety, efficacy, etc.) in fields where satisfaction toward treatment and the contribution of medicine are low.

Sales Strategy for Daikenchuto "While showing year-on-year growth, mitigation of the sense of


abdominal distention also must be an appealing feature."

"Chronic constipation symptoms that are particularly bothersome to patients, and symptoms heavily considered by doctors in diagnosis"

Q. Please indicate the three most troublesome symptoms of your chronic constipation.

medicines.

Q.Please indicate the three most significant symptoms of chronic constipation you consider




Promoting its effects to mitigate the sense of abdominal distention associated with constipation in the growing "constipation" market

TSUMURA & CO.

Sales Strategy for Daikenchuto

■Opinions of doctors on abdominal surgery Q. It is important to improve blood flow in the intestinal tract in the perioperative period. (n = 177)



Surgeons regard "improved intestinal blood flow and enterobacterial conditions" as important in perioperative management.

Questionnaire conducted on m3.com member doctors (Aug. 2019)

Daikenchuto, with its action of improving intestinal blood flow, may promising in satisfying medical demands in perioperative management to enable early ambulation and early discharge.

[Major benefit promoted in the past] Enhancement of enterokinesis



Improvement of intestinal blood flow

TSUMURA & CO.

Sales Strategy for Rikkunshito

Medicinal action of Rikkunshito

- Enterokinesis enhancement(Canine)
- Action on gastric adaptive relaxation (in vitro)

•Action on gastric mucosal injury (Rat)

 Suppression of decreased gastric mucosal blood flow (Rat)
 Action on appetite stimulation (Mouse and rat)

(Mouse and rat)

Rikkunshito features diversified actions, and its efficacy for upper abdominal symptoms of functional dyspepsia (FD) with complicated pathology has been proven in a double-blind comparison study.

FY2019	FY2020	FY2021		
Targeting strategy: Provide information using materials such as the "DREAM Study"*				
Hold academic lectures centering on gastroenterology				
Documentation of new evidential information → Providing more effective sales promotion				
	Targeting strategy: Pr Hold academic lo Offer w	Targeting strategy: Provide information using r "DREAM Study"* Hold academic lectures centering on g Offer web lectures and real le		

Enhancing presence as a remedy for upper gastrointestinal diseases

TSUMURA & CO.

Sales Strategy for Yokukansan

Yokukansan sole promotion



Propose prescription for various symptoms of dementia

Peripheral symptoms and dementia disease course

Institutions employing Yokukansan

dementia disease course Weight loss Wandering Improper behavior	Institutions employing 54 Yokukansan	Approx. 44,000 institutions
HypobuliaWeight lossDelusionDisinhibitionWeight lossFalse recognitionAnxiety / depressionHallucinationsRepetitive behaviorAbulia	Institutions employing 108 Ninjinyoeito	Approx. 21,000 institutions
Prodromal Phase I Phase II Phase II	Institution employing both medicines	Approx. 7,500 institutions

Proposed prescriptions according to the symptoms of dementia

•54 Yokukansan

(Indications: Neurosis, nervousness, etc.)

108 Ninjinyoeito

(Indications: Fatigue, anorexia, etc.)

83 Yokukansankachinpihange

(Indications: Neurosis, nervousness, etc.)

137 Kamikihito

(Indications: Insomnia, dysphoria, etc.)

TSUMURA & CO

Approaches in the Kampo Medicine Seminar

KAMPO Mega Web Lecture

17,878 doctors participated by viewing. (Held on Sep. 25, 2019) \rightarrow Invite them to seminars in their nearest areas.

Introductory Seminar for Postgraduates in Kampo Medicine


In FY2019, 33 seminars will be held throughout Japan. 1,062 participated in the seminars in the April to September period. \rightarrow Among them, 512 were new participants.

Introductory Research Seminar for each domain

Introductory seminars are held in Urological Kampo, Obstetrical & Gynecological Kampo, and Neurosurgical Kampo.

rsumira <u>e co</u>

Approaches to "doctors prescribing 10 or more Kampo products"



Approaches to "doctors prescribing 10 or more Kampo products" are successfully underway.

TSUMURA & CO.

2Q, FY2019

Key Sales Measures in the 2nd Half of the Year

ltem	Details
Gastrointestinal domain	 Daikenchuto: Promote benefits of its effects to mitigate the sense of abdominal distention associated with constipation. Promoting its action to improve intestinal blood flow, and holding presentations for multidisciplinary personnel
	 Rikkunshito: Utilize dual materials* with Daikenchuto, and enhance presence in the upper gastrointestinal prokinetic agent market.
Geriatric field	 Yokukansan: Propose prescription according to various symptoms of dementia. Provide prescription information related to problems with the elderly with regard to "eating, sleeping, and excretion."
Web Lecture Introductory seminar	 Invite viewers of the Web Lecture to the introductory seminar. Hold the second Web Lecture and provide a follow-up plan. Follow up new participants among doctors participating in the introductory seminar in the 1st half of the year.

* Dual material: Material that details two prescriptions at the same time.

TSUMURA & CO.

14

2Q, FY2019

Continuously provide information to attain "sustainable expansion of the Kampo market"



FY2019 Performance Forecasts

FY2019 Performance Forecasts

No changes have been made from the results forecast announced on May 10, 2019.

(¥ million)

TSUMURA & CO.

2Q, FY2019

	FY2018	FY2019	YoY Change	
	F12010	F12019	Amount	Change
Net sales	120,906	125,000	4,093	3.4%
Operating profit	18,520	17,000	(1,520)	(8.2)%
Operating profit margin	15.3%	13.6%	-	-
Ordinary profit	19,702	18,000	(1,702)	(8.6)%
Profit attributable to owners of parent	14,593	12,300	(2,293)	(15.7)%

	FY2018	FY2019 Forecast
Dividends Per share	¥64	¥64
EPS	¥190	¥160
ROE	7.4%	6.0%




Return of Profits to Shareholders

Return of Profits to Shareholders

Policy

- We seek to increase corporate value through the sustainable expansion of the Kampo business and investments to build business foundations in China
- We will bear in mind the state of the mid-to-long term profit levels and cash flow to ensure stable dividends



The year-end dividend and dividend payout ratio for FY2019 are based on the assumption that the dividend item will be approved at the 84th annual shareholders' meeting

TSUMURA & CO.

TSUMURA & CO.

TSUMURA & CO.

20, FY2019

Investor Relations Group

Corporate Communications Dept.

Cautionary items regarding forecasts

- The materials and information provided in this presentation contain so-called forward-looking statements. Readers should be aware that realization of these statements can be affected by a variety of risks and uncertainties and that actual results could differ significantly.
- Changes in the healthcare insurance systems or regulations set by medical treatment authorities on drug prices or other aspects of healthcare or in interest and foreign exchange rates could impact negatively on the Company's performance or financial position.
- In the unlikely event that sales of the Company's core products were halted or declined substantially due to a defect, unforeseen side effect or some other factor, it would have a major impact on the Company's performance or financial position.